(BRITISH JOURNAL OF CLINICAL PHARMACOLOGY)

  Unique cannabis extract found to be safe, tolerable and with no intoxication

The specific pharmaceutical-grade cannabis medicine is currently used in the UK 
and Australia for chronic health conditions including pain, autism, epilepsy, 
anxiety and dementia 

Treatment offers hope for about 43% of UK adults suffering from Chronic Pain 

Medicinal cannabis, company, Bod Australia Limited ("Bod", the "Company") (ASX: 
BDA) has undertaken a Phase I trial of the safety, tolerability and 
pharmacokinetics of cannabidiol (CBD), administered in healthy volunteers 
across multiple formulations, conducted at the Nucleus Network (Melbourne, 
Australia).[1]

The study, published today in leading British Journal of Clinical Pharmacology, 
demonstrates the safety, tolerability and bioavailability of Cannabis sativa – 
Linnea 315CSE extract (available as MediCabilis(TM) Cannabis sativa 50) in oil 
and sublingual wafer formation compared to nabiximols oromucosal spray.

About 43% of the adults in the UK have chronic pain, with as many as 14.3% 
having moderate to severely disabling chronic pain.[2] Chronic pain is highly 
resistant to existing pharmaceutical treatment.[3]

Announcing the publication of the study today, Bod Australia's Chief Scientific 
Officer Dr Adele Hosseini said "the research demonstrates the unique cannabis 
extract's  physiological performance, providing doctors with the confidence to 
prescribe this unique pharmaceutical-grade Cannabis extract, with the 
flexibility of liquid format best suited to the individual needs of their 
patients. Research continues in Motor Neuron Disease (MND), and real-world 
observational studies." said Dr Hosseini.

This research marks a significant development in the use of medical cannabis to 
support thousands of patients who seek relief for the symptoms of chronic 
underlying conditions greatly affecting day-to-day life such as pain, anxiety, 
autism and dementia," she said.

"With over 5500 prescriptions across Australia and the UK, we trust this 
information will support new patients whose doctors may not have considered 
cannabis as an option due specific data being available on the medicines. 
Patients with Chronic Pain, MS, Epilepsy, Anxiety and even Autism that aren't 
getting resolution with their current treatment plan potentially have an 
option, and hope for better quality of life," said Dr Hosseini.

MEDIA INTERVIEWS – Medical professionals & case studies

Dr. Adele Hosseini | Bod Australia | Chief Scientific Officer | 
adele.hosseini@bodaustralia.com |  

www.bodaustralia.com.au  www.bodpharmaceuticals.com 

[1] Adele Hosseini, Andrew McLachlan, Jason Lickliter. A Phase I Trial of the 
Safety, Tolerability, and Pharmacokinetics of Cannabidiol Administered as 
Single-dose Oil Solution and Single and Multiple doses of a Sublingual Wafer in 
Healthy Volunteers. Authorea. July 09, 2020.

[2] Sarah E.E. Mills,Karen P. Nicolson,Blair H. Smith. Chronic pain: a review 
of its epidemiology and associated factors in population-based studies. British 
Journal of Anaesthesia. Elsevier. August 2019

[3] Shirdhya Joypaul, Fiona Kelly, Sara S. McMillan, Michelle A. King.  
Multi-disciplinary interventions for chronic pain involving education: A 
systematic review. October 02, 2019.

SOURCE: Bod Australia